Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax plus Azacitidine Maintenance Therapy in High-Risk AML After Allo-HSCT
NCT07686965Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2030
01
Overview
A Phase 3 trial of lisaftoclax in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07686965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686965.